This clinical trial is focused on studying a condition known as Fibrotic Lung Disease, which involves scarring of the lung tissue that can make breathing difficult. The treatment being tested in this study is called Treprostinil, which is administered as a nebuliser solution. A nebuliser is a device that turns liquid medicine into a mist, making it easier to inhale directly into the lungs. The purpose of this study is to evaluate the long-term safety and tolerability of inhaled Treprostinil in individuals with this lung condition.
Participants in the study will use the Treprostinil nebuliser solution with a device known as the TD-300/A (TD-300), which is part of the Tyvaso Inhalation System. This system includes nebulisers and necessary accessories to help deliver the medication effectively. The study will observe participants over a period to monitor how well they tolerate the treatment and to gather information on any potential side effects.
Throughout the study, researchers will assess various health parameters, such as lung function and overall survival, to understand the effects of continued long-term therapy with Treprostinil. The study aims to provide valuable insights into the treatment’s impact on the progression of Fibrotic Lung Disease and its potential benefits for patients living with this condition.
Belgium 
Denmark 
France 
Germany 
Italy 
Spain 
The Netherlands 
